{"id":"NCT00104247","sponsor":"BioMarin Pharmaceutical","briefTitle":"Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-03","primaryCompletion":null,"completion":"2006-02","firstPosted":"2005-02-25","resultsPosted":"2009-04-16","lastUpdate":"2014-07-23"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonurias"],"interventions":[{"type":"DRUG","name":"sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin","otherNames":[]}],"arms":[],"summary":"The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.","primaryOutcome":{"measure":"Change in Blood Phenylalanine Levels From Baseline to Week 6.","timeFrame":"baseline to week 6","effectByArm":[{"arm":"Sapropterin Dihydrochloride","deltaMin":843,"sd":300},{"arm":"Placebo","deltaMin":888,"sd":323}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["17693179"],"seeAlso":["http://www.bmrn.com","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Upper Respiratory Tract Infection","Headache","Vomiting","Abdominal Pain","Diarrhoea"]}}